5-MeO-DiPT

Summary sheet: 5-MeO-DiPT
5-MeO-DiPT
5-MeO-DiPT.svg
Chemical Nomenclature
Common names 5-MeO-DiPT, Foxy Methoxy, Foxy
Substitutive name 5-Methoxy-diisopropyltryptamine
Systematic name [2-(5-Methoxy-1H-indol-3-yl)ethyl]bis(propan-2-yl)amine
Class Membership
Psychoactive class Psychedelic
Chemical class Tryptamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



⇣ Oral
Dosage
Threshold 3 mg
Light 3 - 10 mg
Common 10 - 15 mg
Strong 15 - 20 mg
Heavy 20 mg +
Duration
Total 4 - 8 hours
Onset 20 - 40 minutes
After effects 2 - 6 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
2C-T-X
2C-X
Cannabis
DOx
MDMA
Mescaline
NBOMe
Amphetamines
Cocaine
DXM
Tramadol
aMT
MAOIs
PCP


5-Methoxy-N,N-diisopropyltryptamine (also known as 5-MeO-DiPT, Foxy, and Foxy Methoxy) is a novel psychedelic substance of the tryptamine class that produces psychedelic effects when administered. It is related in structure to DiPT and 5-MeO-MiPT.

The first human trials of 5-MeO-DiPT were undertaken by Alexander Shulgin in 1975.[1] who would co-author and publish a paper detailing its synthesis and human psychopharmacology in 1981.[2] A summary of the synthesis and reports of human use is included in Shulgin's 1997 book TiHKAL ("Tryptamines I Have Known And Loved").[3]

Anecdotal reports characterize the effects of this compound as highly stimulating and mildly entactogenic, lacking in typical psychedelic visual distortions. Many users report strong physical and tactile effects that serve to enhance libido and sexual pleasure. Many users note an unpleasant body load accompanies higher dosages. Some users also report sound distortion, which is also noted with the related compound, DiPT.

Very little is known about the pharmacological properties, metabolism and toxicity of 5-MeO-DiPT. It is relatively obscure and has a limited history of human use. It has been sold online as a research chemical. It is highly advised to use harm reduction practices if using this substance.

Chemistry

5-MeO-DiPT, or 5-methoxy-N,N-diisopropyltryptamine, is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 5-MeO-DiPT is substituted at R5 of its indole heterocycle with a methoxy (MeO) functional group CH3O−; it also contains two isopropyl chains bound to the terminal amine RN of its tryptamine backbone (DiPT).

5-MeO-DiPT is the N-substituted diisopropyl homolog of 5-MeO-MiPT.

Pharmacology

Further information: Serotonergic psychedelic

The mechanism that produces the purported hallucinogenic and entheogenic effects of 5-MeO-DiPT is thought to result primarily from 5-HT2A receptor agonism, although additional mechanisms of action such as monoamine oxidase inhibition (MAOI) may be involved also.[4] The strongest receptor binding affinity for 5-MeO-DiPT is at the 5-HT1A receptor.[5] However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

5-MeO-DiPT is neurotoxic in rats.[6]</ref>

Subjective effects

 
 This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects
 

Visual effects
 

Cognitive effects
 

Auditory effects
 


Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

 

This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

Further information: Research chemicals § Toxicity and harm potential, and Responsible use § Hallucinogens

The long-term health effects of recreational 5-MeO-DiPT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 5-MeO-DiPT is a research chemical with very little history of human usage. The neurotoxic effects has been studies in rats.[6]

Anecdotal reports suggest that there are no negative health effects attributed to simply trying it by itself at low to moderate doses or using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Overdose

Excessive doses have caused nausea, vomiting, agitation, decreased blood pressure, pupil dilation, increased heart rate, and hallucinations in a number of young adults. Rhabdomyolysis and renal failure occurred in one young man and another one died 3–4 hours after an apparent rectal overdose.[7] A 24-year-old man also died of this compound being administered into the colon.

Tolerance and addiction potential

Like other serotonergic psychedelics, 5-MeO-DiPT is not habit-forming.

Tolerance to the effects of 5-MeO-DiPT builds almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 5-MeO-DiPT presents cross-tolerance with all psychedelics, meaning that after the consumption of 5-MeO-DiPT all psychedelics will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • 2C-T-X - Both classes of compounds can be unpredictable alone.
  • 2C-X - The 5-MeO psychedelics can interact unpredictably to potentiate other psychedelics.
  • Cannabis - May increase the risk of negative psychological effects such as anxiety, paranoia, and psychosis.
  • DOx - The 5-MeO class of tryptamines can be unpredictable in their interactions, particularly increasing the risk of unpleasant physical side effects.
  • MDMA - Some of the 5-MeO tryptamines are a bit unpredictable and should be mixed with MDMA with care.
  • Mescaline - The 5-MeO class of tryptamines can be unpredictable in their interactions.
  • NBOMe - The 5-MeO class of tryptamines can be unpredictable in their interactions and the NBOMes are known to be unpredictable even alone. This combination is best avoided.
  • Amphetamines - The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
  • Cocaine - The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
  • DXM - Little information exists about this combination.
  • Tramadol - Increased risk of serotonin syndrome.
  • aMT - Increased risk of serotonin syndrome.
  • MAOIs - Increased risk of serotonin syndrome.
  • PCP - Little information exists about this combination. May increase risk of psychosis and excessive stimulation.

5-MeO-DiPT is a monoaminergic reuptake inhibitor (MRI).[8][9] 5-MeO-DiPT and MAOIs are a potentially dangerous combination. It is likely that MAOIs could increase the effects of 5-MeO-DiPT unpredictably. Taking this chemical while on prescription MAOIs is strongly discouraged.

Legal status

  • Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[10]
  • China: 5-MeO-DiPT is illegal in China.[11]
  • Denmark: 5-MeO-DiPT is illegal in Denmark.[citation needed]
  • Germany: 5-MeO-DiPT is controlled under Anlage I BtMG (Narcotics Act, Schedule I)[12] as of October 10, 2000.[13] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[14]
  • Greece: 5-MeO-DiPT is illegal in Greece.[citation needed]
  • Japan: 5-MeO-DiPT is illegal in Japan.[citation needed]
  • Latvia: 5-MeO-DiPT is illegal in Latvia.[citation needed]
  • New Zealand: 5-MeO-DiPT can be considered an analogue of DMT, which makes it a Class C controlled drug in New Zealand.[15]
  • Singapore: 5-MeO-DiPT is illegal in Singapore.[citation needed]
  • Sweden: 5-MeO-DiPT is illegal in Sweden.[16]
  • Switzerland: 5-MeO-DiPT is a controlled substance specifically named under Verzeichnis E.[17]
  • United Kingdom: 5-MeO-DiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-DiPT, which is a Class A drug as a result of the tryptamine catch-all clause.[18]
  • United States: 5-MeO-DiPT is a Schedule 1 controlled substance. On April 4, 2003, the United States DEA added both 5-MeO-DiPT and αMT to Schedule I of the Controlled Substances Act under "emergency scheduling" procedures. The drugs were officially placed into Schedule I on September 29, 2004.[19]

See also

External links

Discussion

References

  1. ↑ Alexander Shulgin (1976). Pharmacology Notes I (The Shulgin Lab Books) (PDF). Lafayette, CA: Erowid. p. 176. 
  2. ↑ Shulgin, A. T.; Carter, M. F. (1980). "N, N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity". Communications in psychopharmacology. 4 (5): 363–369. ISSN 0145-5699. OCLC 3012956. PMID 6949674. 
  3. ↑ Shulgin, Alexander; Shulgin, Ann (1997). TiHKAL: The Continuation. United States: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252. 
  4. ↑ Nagai, F.; Nonaka, R.; Satoh, K.; Kamimura, H. (2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology. 559 (2–3): 132–137. doi:10.1016/j.ejphar.2006.11.075. eISSN 1879-0712. ISSN 0014-2999. OCLC 01568459. PMID 17223101. 
  5. ↑ Ray, T. S. (2 February 2010). Manzoni, O. J., ed. "Psychedelics and the Human Receptorome". PLoS ONE. 5 (2): e9019. doi:10.1371/journal.pone.0009019. ISSN 1932-6203. 
  6. ↑ 6.0 6.1 Noworyta-Sokołowska, K.; Kamińska, K.; Kreiner, G.; Rogóż, Z.; Gołembiowska, K. (2016). "Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats". Neurotoxicity Research. 30 (4): 606–619. doi:10.1007/s12640-016-9654-0. eISSN 1476-3524. ISSN 1029-8428. OCLC 50166444. PMC 5047954  . PMID 27461536. 
  7. ↑ Randall C. Baselt (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, CA: Biomedical Publications. pp. 975–976. ISBN 978-0-9626523-7-0. ISSN 0009-9147. 
  8. ↑ Tayebati, S. K.; Tomassoni, D.; Nwankwo, I. E.; Di Stefano, A.; Sozio, P.; Cerasa, L. S.; Amenta, F. (2013). "Modulation of monoaminergic transporters by choline-containing phospholipids in rat brain". Drug Targets - CNS & Neurological Disorders. 12 (1): 94–103. doi:10.2174/1871527311312010015. ISSN 1568-007X. PMID 23244432. 
  9. ↑ Trabucchi, M.; Govoni, S.; Battaini, F. (1986). "Changes in the interaction between CNS cholinergic and dopaminergic neurons induced by L-alpha-glycerylphosphorylcholine, a cholinomimetic drug". Il Farmaco, Edizione Scientifica. 41 (4): 325–334. ISSN 0430-0920. OCLC 1064491979. PMID 3709792. 
  10. ↑ "RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016" (in Portuguese). Agência Nacional de Vigilância Sanitária (Anvisa) [National Sanitary Surveillance Agency]. December 5, 2016. Retrieved January 8, 2020. 
  11. ↑ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). 国家食品药品监督管理总局 [China Food and Drug Administration (CFDA)]. September 27, 2015. Archived from the original on September 6, 2017. Retrieved August 19, 2020. 
  12. ↑ "Gesetz über den Verkehr mit Betäubungsmitteln: Anlage I" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  13. ↑ "Vierzehnte Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften". Bundesgesetzblatt Jahrgang 2000 Teil I Nr. 44 (in German). Bundesanzeiger Verlag (published September 30, 2000). September 27, 2000. pp. 1414–1415. ISSN 0341-1095. Retrieved December 18, 2019. 
  14. ↑ "Gesetz über den Verkehr mit Betäubungsmitteln: § 29" (in German). Bundesamt für Justiz [Federal Office of Justice]. Retrieved December 10, 2019. 
  15. ↑ "Schedule 1: Class A controlled drugs". Misuse of Drugs Act 1975. Parliamentary Counsel Office (PCO). Retrieved September 19, 2020. 
  16. ↑ "Svensk författningssamling Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor" (PDF) (in Swedish) (published September 7, 2004). August 19, 2004. SFS 2004:696. 
  17. ↑ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  18. ↑ "Schedule 2: Part I: Class A Drugs". "Misuse of Drugs Act 1971". UK Government. Retrieved August 20, 2020. 
  19. ↑ Schedules of Controlled Substances: Placement of Alpha- Methyltryptamine and 5-Methoxy-N,N-Diisopropyltryptamine Into Schedule I 
Retrieved from ‘https://psychonautwiki.org/w/index.php?title=5-MeO-DiPT&oldid=153343’